Me2H3K9 at the HD locus in R6/1 and R6/2 striatum and cerebellum.

<p>A. Schematic representation of the human HD transgene expressed in R6 mice and of the corresponding region in <i>Hdh</i>. The arrows show locations of the primers used to assess chromatin structure. B. ChIP analysis from the striatum (ST) and the cerebellum (CB) of R6/1 and R6/2 mice using antibody to Me2H3K9. R6/1 mice at early- and/or late-pathological stages (13- and 36-wk) and R6/2 mice at late-pathological stage (12-wk) were used. Error bars, sem; *, inter-tissue comparisons; §, inter-mouse line comparisons. *, p<0.05; §, p<0.05; §§, p<0.01, §§§, p<0.001. C. Global analysis of the level of Me2H3K9 at the HD locus. The mean levels of Me2H3K9 at the HD locus, corresponding to mean ChIP values at the HD promoter and HD intron-1, were calculated for the striatum and cerebellum of R6/1 mice at early and late-pathological stages (13- and 36-wk) and for the striatum and cerebellum of R6/2 mice at late pathological stage (12-wk). Error bars, sem; §, p<0.05; §§, p<0.01. D. Correlative analysis of CAG instability rates with mean levels of Me2H3K9 at the HD locus. R6/1 mice of 13 and 36 weeks and R6/2 mice of 12 weeks were used for correlation analysis E. ChIP analyses of the HD locus from lymphoblast cell lines derived from HD patients and control individuals (CT), using antibody to Me2H3K9. The values correspond to mean values calculated from ChIP performed from 4 HD cell lines and 2 control cell lines.